All In Biotech

Investigational drug · Phase 3

64Cu-SAR-bisPSMA

Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Prostate Cancer, Prostatic Neoplasms, Castration-Resistant, Prostatic Neoplasms.

Phase 3

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

3

3 still active

All registered trials

6

Any phase or sponsor naming "64Cu-SAR-bisPSMA"

First trial start

2021

Aug 11, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "64Cu-SAR-bisPSMA", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Prostate Cancer
  • Prostatic Neoplasms, Castration-Resistant
  • Prostatic Neoplasms
  • Prostate Cancer Patients With Detectable PSA Following Prostatectomy
  • Prostate Cancer Recurrent
  • Prostate Cancer Patients Who Have Brachytherapy Seed Implant
  • Prostate Cancer Patients Treated by Radiotherapy
  • Cryotherapy

Approved drugs for the same conditions: Prostate cancer · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "64Cu-SAR-bisPSMA" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Prostate Cancer

  • AdabelimumabSHR-A2102, SHR2554Phase 320 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • SaruparibAZD5305Phase 310 trials

    AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer

  • QLC5508MHB088CPhase 39 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma

  • aglatimagene besadenovecCAN-2409, AdV-tkPhase 35 trials

    Candel Therapeutics, Inc. · Prostate Cancer, Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)

  • Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials

    Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

  • MevrometostatPF-06821497Phase 33 trials

    Pfizer · Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer

  • 177Lu-NYM032Phase 32 trials

    Norroy Bioscience Co., LTD · Prostate Cancer, Metastatic Castration-resistant Prostate Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.